1952
- New Beginnings
-
Therapeutic Pharmaceuticals
The Company is founded by Mr. K.P. Menon and Mr. K.H. Shah. Headquartered in Bombay, India, the company starts production with a focus on research in anti-TB therapy. In its first year, Therapeutic introduces a first-time product for Tuberculosis therapy, ISOPASCAL-CD, an Isoniazid-PAS combination in tablet form.
1955
- New Innovation
-
Pioneering Research
Company introduces a Lysine and Calcium based formulation for pediatric and geriatric use - A pioneer product of Therapeutic.
1961
- New Identity
-
Company Reformation
Mr K.P.Menon takes over the management of the company along with his brother Mr. P.P Menon. Therapeutic continues to operate from Bombay with research continuing on newer formulations and dosage forms. The company collaborates with Chinoin, Hungary (now Sanofi) to market tetracycline for the Indian market.
1962
- New Products
-
World's First
For the first time in the world, Paracetamol is solubilized and presented in an oral dosage form at a strength of 150 mg/ml as Aeknil Drops. Product targeted for pediatric population. This product then evolved to Aeknil Syrup, which is Paracetamol 150 mg /5ml in a flavoured syrupy base. Aeknil tablets also introduced at 500 mg strength.
1963
-
Solucort Drops
Therapeutic introduces another first-time in the world product, Solucort Drops, which is Prednisolone solubilized in an aqueous base as a palatable chocolate flavored drops.
1968
-
AEKNIL Injection
Aeknil Injection, the first Paracetamol solution for injection in the world is introduced. Therapeutic's R&D team responsible for solubilizing and stabilizing Paracetamol in a convenient injectable form at a never before strength of 150 mg/ml. Product is very well received by the medical fraternity and several clinical trials performed with this product.
1970
-
International Presence
Aeknil Injection along with tablet and liquid dosage forms exported to South East Asian nations - Philippines, Malaysia, and Thailand.
1980
-
Aeknil Injection Brand of Choice
Aeknil displaces dipyrone as the preferred Injection for the treatment of pyrexia and analgesia. This was brought about in view of the safety concerns of Dipyrone. Aeknil displaces Analgin as the preferred choice due its superior safety and minimal side effects, especially in pediatric population. Aeknil range of products makes inroads to the Gulf markets. Well received in the UAE and Saudi Arabia.
1990
-
Rapid Strides
Aeknil increases its presence in the African continent by exporting to countries like Ghana and Nigeria.
2000
-
AEKNIL Injection for I.V use
The Company introduces Aeknil Injection for Intravenous (I.V) use at 150 mg / ml in 2 ml, 3 ml Ampoules delivering 300 to 450 mg of Paracetamol per unit.
2012
-
Pursuit of Excellence
In keeping with market trends, Aeknil Infusion (1g /100 ml) and Aeknil 650 mg tablets introduced.